Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of drugs shows promise for tough lung cancer

NCT ID NCT03829319

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether adding the targeted therapy lenvatinib to a standard combination of immunotherapy (pembrolizumab) and chemotherapy could help people with a common type of advanced lung cancer live longer. The study enrolled 761 adults with metastatic nonsquamous non-small cell lung cancer who had not received prior treatment. Researchers compared the four-drug combo against the standard three-drug regimen to see if it delayed cancer growth or improved survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lenvatinib (a targeted therapy) combined with pembrolizumab (an immunotherapy) and chemotherapy (pemetrexed plus carboplatin or cisplatin)
What this could lead to
If successful, this combination could become a new first-line treatment option for people with metastatic nonsquamous non-small cell lung cancer, potentially improving how long they live without their cancer growing.
What could go wrong
This is a completed phase 3 trial, but results are not yet widely available. Adding lenvatinib may increase side effects like high blood pressure, bleeding, or fatigue, and it may not improve survival enough to outweigh those risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

761 people

The number who actually took part.

Started

Mar 2019

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer \[AJCC\], version 8 or current version), nonsquamous NSCLC. * Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation). * Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation. * Provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (not previously irradiated). * Life expectancy of at least 3 months. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization. * Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed. * Male participants must agree for at least 7 days after the last dose of lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents to: 1. Refrain from donating sperm PLUS either: 2. Be abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR 3. Must agree to use contraception unless confirmed to be azoopsermic (vasectomized or secondary to medical cause) as detailed below: 1. Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration. Note: 7 days after lenvatinib/matching placebo is stopped, if the participant is on pembrolizumab only and is greater than 180 days post chemotherapy, no male contraception measures are needed. * Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1. Is not a WOCBP OR 2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab and/or 30 days post-lenvatinib/matching placebo, and up to 180 days post last dose of chemotherapeutic agents, whichever occurs last. * Adequate organ function. * Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as \>150/90 mm Hg for \>4 weeks despite standard medical management. Exclusion Criteria: * Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention. * History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease. * Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Additionally, the degree of proximity to major blood vessels should be considered for exclusion because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib-therapy. (In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta). * Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers. * Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention. * Has had allogeneic tissue/solid organ transplant. * Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority. * Known history of Hepatitis B or active Hepatitis C. No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority. * History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption. * Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention. * Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability. * Known history of active tuberculosis. * Active infection requiring systemic therapy. * Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention. * Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed. * A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. * Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula. * Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC. * Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor. * Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of \>30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. * Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention. * Received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: killed vaccines are allowed. * Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention. * Has a prolongation of QTc interval (calculated using Fridericia's formula) of \>480 msecl. * Left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO). * Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonsquamous non small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonsquamous non small cell lung cancer

Contacts and locations

Locations

  • Aberdeen Royal Infirmary ( Site 0288)

    Aberdeen, Scotland, AB25 2ZN, United Kingdom

  • Abington Hospital - Asplundh Cancer Center ( Site 0575)

    Willow Grove, Pennsylvania, 19090, United States

  • Ankara Sehir Hastanesi ( Site 0323)

    Ankara, 06800, Turkey (Türkiye)

  • Ankara Universitesi Tip Fakultesi. ( Site 0317)

    Ankara, 06620, Turkey (Türkiye)

  • Auckland City Hospital ( Site 0011)

    Auckland, 1023, New Zealand

  • Ballarat Health Services ( Site 0003)

    Ballarat, Victoria, 3350, Australia

  • Beijing Cancer Hospital ( Site 0120)

    Beijing, Beijing Municipality, 100036, China

  • Blacktown Hospital Western Sydney Local Health District ( Site 0008)

    Blacktown, New South Wales, 2148, Australia

  • Bradford Hill Centro de Investigaciones Clinicas ( Site 0387)

    Santiago, Region M. de Santiago, 8420383, Chile

  • Broome Oncology, LLC ( Site 0562)

    Johnson City, New York, 13790, United States

  • CEMAIC ( Site 0374)

    Córdoba, X5008HHW, Argentina

  • CEMIC ( Site 0370)

    Buenos Aires, Buenos Aires F.D., C1431FWO, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0372)

    San Juan, J5402DIL, Argentina

  • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0403)

    Québec, Quebec, G1R 2J6, Canada

  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0412)

    Montreal, Quebec, H3T 1M5, Canada

  • CIUSSS de la Mauricie et du Centre du Quebec ( Site 0408)

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • Cairns Hospital ( Site 0002)

    Cairns, Queensland, 4870, Australia

  • Cambridge University Hospitals NHS Trust ( Site 0293)

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)

    Urumuqi, Xinjiang, 830000, China

  • Cancer Hospital Chinese Academy of Medical Science ( Site 0117)

    Beijing, Beijing Municipality, 100021, China

  • Central Clinical Hospital with outpatient Clinic ( Site 0262)

    Moscow, Moscow, 121359, Russia

  • Centre Paul Strauss ( Site 0144)

    Strasbourg, Bas-Rhin, 67065, France

  • Centre de Cancerologie du Grand Montpellier ( Site 0142)

    Montpellier, Herault, 34070, France

  • Centro Oncologico Antofagasta ( Site 0386)

    Antofagasta, 1240000, Chile

  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0380)

    Temuco, Araucania, 4810218, Chile

  • Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0367)

    Berazategui, Buenos Aires, B1884BBF, Argentina

  • Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0601)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Chris OBrien Lifehouse ( Site 0006)

    Sydney, New South Wales, 2050, Australia

  • Christie NHS Foundation Trust ( Site 0275)

    Manchester, M20 4BX, United Kingdom

  • Chungbuk National University Hospital ( Site 0062)

    Cheongju-si, North Chungcheong, 28644, South Korea

  • City Clinical Hospital 1 na. NI. Pirogov ( Site 0270)

    Moscow, Moscow, 119049, Russia

  • Clinica Universidad Catolica del Maule ( Site 0385)

    Talca, Maule Region, 3465584, Chile

  • Complejo Hospitalario Universitario A Coruna ( Site 0239)

    A Coruña, La Coruna, 15006, Spain

  • Complejo Hospitalario de Malaga ( Site 0238)

    Málaga, 29010, Spain

  • Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0314)

    Adana, 01330, Turkey (Türkiye)

  • Ege Universitesi Tip Fakultesi ( Site 0313)

    Izmir, 35100, Turkey (Türkiye)

  • El Camino Hospital Cancer Center ( Site 0529)

    Mountain View, California, 94040, United States

  • FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0264)

    Moscow, Moscow, 125367, Russia

  • First Affiliated Hospital of The Third Military Medical University ( Site 0118)

    Chongqing, Chongqing Municipality, 400038, China

  • First Pavlov State Medical University of Saint Petersburg-Department of Oncology ( Site 0273)

    Saint Petersburg, Sankt-Peterburg, 197022, Russia

  • Fujian Provincial Cancer Hospital ( Site 0102)

    Fuzhou, Fujian, 350014, China

  • Fujita Health University Hospital ( Site 0016)

    Toyoake, Aichi-ken, 470-1192, Japan

  • Fundacion Arturo Lopez Perez FALP ( Site 0383)

    Santiago, Region M. de Santiago, 7500921, Chile

  • Good Samaritan Hospital Corvallis ( Site 0521)

    Corvallis, Oregon, 97330, United States

  • Guys and St Thomas NHS Foundation Trust ( Site 0280)

    London, London, City of, SE1 9RT, United Kingdom

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0310)

    Istanbul, 34722, Turkey (Türkiye)

  • Hacettepe Universitesi Tıp Fakultesi ( Site 0316)

    Ankara, 06100, Turkey (Türkiye)

  • Hamato-Onkologie Hamburg Prof. Laack und Partner ( Site 0161)

    Hamburg, 20251, Germany

  • Henan Cancer Hospital ( Site 0112)

    Zhengzhou, Henan, 450008, China

  • Henry Ford Health System ( Site 0563)

    Detroit, Michigan, 48202, United States

  • Holy Cross Hospital ( Site 0512)

    Fort Lauderdale, Florida, 33308, United States

  • Holy Family Hospital ( Site 0228)

    Nazareth, 1641101, Israel

  • Hopital Cardiologique Louis Pradel ( Site 0141)

    Bron, Auvergne-Rhône-Alpes, 69500, France

  • Hopital Cite de la Sante de Laval ( Site 0400)

    Laval, Quebec, H7M 3L9, Canada

  • Hopital Cochin ( Site 0140)

    Paris, 75014, France

  • Hopital Foch ( Site 0145)

    Suresnes, Hauts-de-Seine, 92151, France

  • Hopital Laennec ( Site 0146)

    Nantes, Loire-Atlantique, 44093, France

  • Hopital Nord du Marseille ( Site 0147)

    Marseille, Bouches-du-Rhone, 13015, France

  • Hopital Robert Schuman ( Site 0143)

    Vantoux, Moselle, 57070, France

  • Hospital Aleman ( Site 0368)

    Buenos Aires, C1118AAT, Argentina

  • Hospital Clinico San Carlos ( Site 0235)

    Madrid, 28040, Spain

  • Hospital General Universitario Gregorio Maranon ( Site 0237)

    Madrid, 28009, Spain

  • Hospital General Universitario de Alicante ( Site 0240)

    Alicante, 03010, Spain

  • Hospital General Universitario de Valencia ( Site 0231)

    Valencia, Valenciana, Comunitat, 46014, Spain

  • Hospital Santa Creu i Sant Pau ( Site 0241)

    Barcelona, 08025, Spain

  • Hospital Universitario Insular de Gran Canaria ( Site 0244)

    Las Palmas de Gran Canaria, Las Palmas, 35001, Spain

  • Hospital Universitario La Fe ( Site 0233)

    Valencia, Valenciana, Comunitat, 46026, Spain

  • Hospital Universitario La Paz ( Site 0236)

    Madrid, 28046, Spain

  • Hospital Universitario Miguel Servet ( Site 0242)

    Zaragoza, 50009, Spain

  • Hubei Cancer Hospital ( Site 0122)

    Wuhan, Hubei, 430079, China

  • ICO L Hospitalet ( Site 0234)

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Inonu Universitesi Medical Fakultesi ( Site 0318)

    Malatya, 44280, Turkey (Türkiye)

  • Instituto Medico Especializado Alexander Fleming ( Site 0369)

    Buenos Aires, C1426ANZ, Argentina

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0371)

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0312)

    Istanbul, 34098, Turkey (Türkiye)

  • Jilin Cancer Hospital ( Site 0115)

    Changchun, Jilin, 130103, China

  • Juravinski Cancer Centre ( Site 0407)

    Hamilton, Ontario, L8V 1C3, Canada

  • Kanazawa University Hospital ( Site 0018)

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kansai Medical University Hospital ( Site 0022)

    Hirakata, Osaka, 573-1191, Japan

  • Kingston Health Sciences Centre ( Site 0414)

    Kingston, Ontario, K7L 2V7, Canada

  • Klinikum Esslingen GmbH ( Site 0164)

    Esslingen am Neckar, Baden-Wurttemberg, 73730, Germany

  • Krankenhaus Martha Maria Halle-Doelau ( Site 0166)

    Halle, Saxony-Anhalt, 06120, Germany

  • Krankenhaus Nordwest ( Site 0169)

    Frankfurt am Main, Hesse, 60488, Germany

  • L'hopital Nord-Ouest - Centre Hospitalier de Villefranche sur Saone ( Site 0149)

    Villefranche-sur-Saône, Rhone, 69655, France

  • Lakeridge Health ( Site 0406)

    Oshawa, Ontario, L1G 2B9, Canada

  • Leeds Teaching Hospital NHS Trust. St. James University Hospital ( Site 0276)

    Leeds, LS9 7TF, United Kingdom

  • Leicester Royal Infirmary ( Site 0284)

    Leicester, LE1 5WW, United Kingdom

  • Leningrad Regional Oncology Center ( Site 0271)

    Saint Petersburg, Leningradskaya Oblast', 197758, Russia

  • LungenClinic Grosshansdorf GmbH ( Site 0171)

    Großhansdorf, Schleswig-Holstein, 22927, Germany

  • MED-POLONIA Sp. z o.o. ( Site 0609)

    Poznan, Greater Poland Voivodeship, 60-693, Poland

  • Meir Medical Center ( Site 0221)

    Kfar Saba, 4428164, Israel

  • Mercy Health-Paducah Medical Oncology and Hematology ( Site 0570)

    Paducah, Kentucky, 42003, United States

  • Moncton Hospital - Horizon Health Network ( Site 0410)

    Moncton, New Brunswick, E1C 6Z8, Canada

  • Moscow Regional Oncological Dispensary ( Site 0274)

    Balashikha, Moscow Oblast, 143900, Russia

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Cancer Center ( Site 0061)

    Goyang-si, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital ( Site 0026)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 0024)

    Kashiwa, Chiba, 277-8577, Japan

  • National Hospital Organization Nagoya Medical Center ( Site 0017)

    Nagoya, Aichi-ken, 460-0001, Japan

  • National Medical Research Radiology Centre ( Site 0260)

    Moscow, Moscow, 125284, Russia

  • Niigata Cancer Center Hospital ( Site 0019)

    Niigata, 951-8566, Japan

  • Nizhniy Novgorod Region Oncology Dispensary ( Site 0272)

    Nizhny Novgorod, Nizhny Novgorod Oblast, 603081, Russia

  • North Middlesex University Hospital NHS Trust ( Site 0291)

    London, London, City of, N18 1QX, United Kingdom

  • Nottingham City Hospital Campus ( Site 0287)

    Nottingham, NG5 1PB, United Kingdom

  • Omsk Clinical Oncology Dispensary ( Site 0267)

    Omsk, Omsk Oblast, 644013, Russia

  • Oncocentro ( Site 0384)

    Viña del Mar, Valparaiso, 2520598, Chile

  • OrlandiOncologia ( Site 0381)

    Santiago, Region M. de Santiago, 7500713, Chile

  • Osaka Habikino Medical Center ( Site 0020)

    Habikino, Osaka, 583-8588, Japan

  • Parkland Health & Hospital System ( Site 0576)

    Dallas, Texas, 75235, United States

  • Peking Union Medical College Hospital ( Site 0108)

    Beijing, Beijing Municipality, 100006, China

  • Pius Hospital Oldenburg ( Site 0170)

    Oldenburg, Lower Saxony, 26121, Germany

  • Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 0615)

    Pleszew, Greater Poland Voivodeship, 63-300, Poland

  • Pontificia Universidad Catolica de Chile ( Site 0382)

    Santiago, Region M. de Santiago, 8330032, Chile

  • Port Macquarie Base Hospital ( Site 0001)

    Port Macquarie, New South Wales, 2444, Australia

  • Rabin Medical Center ( Site 0224)

    Petah Tikva, 4941492, Israel

  • Rambam Medical Center ( Site 0223)

    Haifa, 3109601, Israel

  • SAHI Republican Clinical Oncological Dispensary of the MoH of RT ( Site 0261)

    Kazan', Tatarstan, Respublika, 420029, Russia

  • Saint Lukes Cancer Institute ( Site 0541)

    Kansas City, Missouri, 64111, United States

  • Sanatorio Parque ( Site 0365)

    Rosario, Santa Fe Province, S2000DSV, Argentina

  • Sanford Health Roger Maris Cancer Center ( Site 0533)

    Fargo, North Dakota, 58122, United States

  • Sault Area Hospital ( Site 0413)

    Sault Ste. Marie, Ontario, P6B 0A8, Canada

  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0269)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Severance Hospital Yonsei University Health System ( Site 0063)

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center-Oncology ( Site 0229)

    Jerusalem, 9013102, Israel

  • Shamir Medical Center-Assaf Harofeh ( Site 0227)

    Ẕerifin, 70300, Israel

  • Shanghai Pulmonary Hospital ( Site 0101)

    Shanghai, Shanghai Municipality, 200443, China

  • Sheba Medical Center ( Site 0220)

    Ramat Gan, 5262000, Israel

  • Soroka Medical Center ( Site 0222)

    Beersheba, 8410101, Israel

  • Sourasky Medical Center ( Site 0225)

    Tel Aviv, 6423906, Israel

  • Southern Medical University Nanfang Hospital ( Site 0121)

    Guangzhou, Guangdong, 510515, China

  • St Georges University Hospitals NHS Foundation Trust. ( Site 0292)

    London, London, City of, SW17 0QT, United Kingdom

  • Stephenson Cancer Center ( Site 0504)

    Oklahoma City, Oklahoma, 73104, United States

  • Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0602)

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • Tauranga Hospital ( Site 0004)

    Tauranga, Bay of Plenty, 3112, New Zealand

  • The Cancer Institute Hospital of JFCR ( Site 0021)

    Tokyo, 135-8550, Japan

  • The Catholic University of Korea St. Vincent s Hospital ( Site 0064)

    Gyeonggi-do, Kyonggi-do, 16247, South Korea

  • The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0286)

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • The First Affiliated Hospital Zhejiang University ( Site 0109)

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)

    Wenzhou, Zhejiang, 325000, China

  • The Prince Charles Hospital ( Site 0010)

    Chermside, Queensland, 4032, Australia

  • The Second Hospital Affiliated to AMU ( Site 0119)

    Chongqing, Chongqing Municipality, 400037, China

  • The Third Affiliated Hospital of Harbin Medical University ( Site 0100)

    Harbin, Heilongjiang, 150081, China

  • Thomas Jefferson University Hospital ( Site 0548)

    Philadelphia, Pennsylvania, 19107, United States

  • Tianjin Medical University Cancer Institute & Hospital ( Site 0111)

    Tianjin, Tianjin Municipality, 300060, China

  • Tokyo Metropolitan Komagome Hospital ( Site 0015)

    Tokyo, 113-8677, Japan

  • UT Southwestern Medical Center ( Site 0558)

    Dallas, Texas, 75390, United States

  • Uniklinik RWTH Aachen ( Site 0160)

    Aachen, North Rhine-Westphalia, 52074, Germany

  • Universitaetsklinikum des Saarlandes ( Site 0165)

    Homburg, Saarland, 66421, Germany

  • Utah Cancer Specialists ( Site 0523)

    Salt Lake City, Utah, 84106, United States

  • Wakayama Medical University Hospital ( Site 0025)

    Wakayama, 641-8510, Japan

  • West Cancer Center - East Campus ( Site 0544)

    Germantown, Tennessee, 38138, United States

  • West Virginia University ( Site 0526)

    Morgantown, West Virginia, 26506, United States

  • Westmead Hospital ( Site 0009)

    Sydney, New South Wales, 2145, Australia

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 0613)

    Lodz, Łódź Voivodeship, 93-513, Poland

  • Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0123)

    Wuhan, Hubei, 430022, China

  • Yale University ( Site 0519)

    New Haven, Connecticut, 06520-8028, United States

  • Zhejiang Cancer Hospital ( Site 0113)

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University ( Site 0103)

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.